OncoMatch/Clinical Trials/NCT02215889
Partial Liver Segment 2/3 Transplantation Study
Is NCT02215889 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for colorectal cancer.
The patients will receive hepatectomy as a 2 stage procedure. In the first surgical procedure liver segments 2-3 are removed and liver donor segments 2-3 inserted. After growth of donor segments 2-3, the remaining liver segments of the recipient are removed. The patient will at this time have only donor liver tissue in place.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
All patients should have received at least 8 weeks of chemotherapy.
Cannot have received: palliative resection of primary CRC tumor
Palliative resection of primary CRC tumor.
Lab requirements
Blood counts
Hb >10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >75
Kidney function
Creatinine <1.25 x upper normal level
Liver function
Bilirubin <2 x upper normal level, ASAT, ALAT <5 x upper normal level, Albumin above lower normal level
Satisfactory blood tests: Hb >10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >75, Bilirubin<2 x upper normal level, ASAT,ALAT<5 x upper normal level, Creatinine <1.25 x upper normal level. Albumin above lower normal level.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02215889 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior palliative resection of primary CRC tumor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages